NASDAQ:LGVN Longeveron (LGVN) Stock Price, News & Analysis → Top 5 AI Stocks to Buy for 2024 (From Market Moving Trends) (Ad) Free LGVN Stock Alerts $2.94 +0.25 (+9.31%) (As of 02:46 PM ET) Add Compare Share Share Today's Range$2.90▼$4.1050-Day Range$0.82▼$3.5352-Week Range$0.77▼$40.00Volume90.18 million shsAverage Volume4.36 million shsMarket Capitalization$18.67 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Longeveron alerts: Email Address Longeveron MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside284.6% Upside$12.00 Price TargetShort InterestHealthy1.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.97Based on 4 Articles This WeekInsider TradingAcquiring Shares$350,000 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($4.70) to ($3.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.44 out of 5 starsMedical Sector472nd out of 917 stocksPharmaceutical Preparations Industry219th out of 431 stocks 3.5 Analyst's Opinion Consensus RatingLongeveron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageLongeveron has only been the subject of 1 research reports in the past 90 days.Read more about Longeveron's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.31% of the float of Longeveron has been sold short.Short Interest Ratio / Days to CoverLongeveron has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Longeveron has recently increased by 18.24%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLongeveron does not currently pay a dividend.Dividend GrowthLongeveron does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LGVN. Previous Next 2.8 News and Social Media Coverage News SentimentLongeveron has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Longeveron this week, compared to 1 article on an average week.Search Interest17 people have searched for LGVN on MarketBeat in the last 30 days. This is an increase of 42% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Longeveron to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Longeveron insiders have bought more of their company's stock than they have sold. Specifically, they have bought $350,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders19.12% of the stock of Longeveron is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.01% of the stock of Longeveron is held by institutions.Read more about Longeveron's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Longeveron are expected to grow in the coming year, from ($4.70) to ($3.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Longeveron is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Longeveron is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLongeveron has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Longeveron's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIDo NOT Buy the Fidelity and Blackrock Bitcoin ETFs - Here’s whyBefore you buy the newly approved Bitcoin ETFs… Take a look at this “Better than Bitcoin ticker” you can buy in any regular brokerage account. Why? Because it’s been shown to outperform Bitcoin by 10X or more during the past four bull runs… For example, while Bitcoin surged 985% during the last bull run in 2021… This is your best chance at it. About Longeveron Stock (NASDAQ:LGVN)Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.Read More LGVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LGVN Stock News HeadlinesJune 13 at 8:15 AM | investorplace.comWhy Is Longeveron (LGVN) Stock Up 46% Today?June 12 at 4:45 PM | investorplace.comWhy Is Longeveron (LGVN) Stock Up 120% Today?June 9, 2024 | americanbankingnews.comLongeveron (NASDAQ:LGVN) Stock Price Down 1%June 3, 2024 | globenewswire.comLongeveron® Announces Contract Development and Manufacturing Business and First ContractMay 29, 2024 | benzinga.comAcumen Pharmaceuticals Stock (NASDAQ:ABOS), Quotes and News SummaryMay 28, 2024 | globenewswire.comLongeveron® to Attend BIO International Convention 2024May 17, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Longeveron (LGVN) and EDAP TMS (EDAP)May 14, 2024 | investorplace.comLGVN Stock Earnings: Longeveron Beats EPS, Beats Revenue for Q1 2024May 14, 2024 | globenewswire.comLongeveron Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 10, 2024 | globenewswire.comLongeveron Announces Board of Directors Planned TransitionsMay 2, 2024 | globenewswire.comLongeveron to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024May 1, 2024 | finance.yahoo.comLongeveron Inc. (LGVN)April 25, 2024 | globenewswire.comLongeveron to Present at the Planet MicroCap ShowcaseApril 20, 2024 | investing.comLongeveron secures $11.4 million from warrant exercisesApril 18, 2024 | globenewswire.comLongeveron Raises a Total of $11.4 Million in Gross Proceeds from Warrant Exercise Offering and Public OfferingApril 17, 2024 | globenewswire.comLongeveron Announces Exercise of Warrants for $6.2 Million Gross ProceedsApril 15, 2024 | msn.comLongeveron stock rallies 85% on Alzheimer's presentation (update)April 15, 2024 | msn.comWhat's Going On With Longeveron Stock?April 15, 2024 | markets.businessinsider.comWhy Is Longeveron (LGVN) Stock Up 48% Today?April 15, 2024 | finance.yahoo.comLongeveron’s CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer’s Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer’s Association International Conference (AAIC)April 15, 2024 | globenewswire.comLongeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)April 15, 2024 | investorplace.comWhy Is Longeveron (LGVN) Stock Up 48% Today?April 13, 2024 | finance.yahoo.comChief Scientific Officer Joshua Hare Acquires 148,936 Shares of Longeveron Inc (LGVN)April 11, 2024 | globenewswire.comLongeveron Announces Closing of $5.2 Million Public OfferingApril 8, 2024 | globenewswire.comLongeveron Announces Pricing of $5.25 Million Public OfferingSee More Headlines Receive LGVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Longeveron and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/14/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LGVN CUSIPN/A CIK1721484 Webwww.longeveron.com Phone305-302-7158FaxN/AEmployees23Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+346.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($9.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-21,410,000.00 Net Margins-2,129.24% Pretax Margin-2,129.24% Return on Equity-300.96% Return on Assets-164.96% Debt Debt-to-Equity RatioN/A Current Ratio0.71 Quick Ratio0.71 Sales & Book Value Annual Sales$710,000.00 Price / Sales24.06 Cash FlowN/A Price / Cash FlowN/A Book Value$2.68 per share Price / Book1.00Miscellaneous Outstanding Shares6,350,000Free Float5,135,000Market Cap$17.08 million OptionableNot Optionable Beta0.33 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Joshua Michael Hare FACC (Age 61)M.D., Co-Founder, Chief Science Officer & Chairman Comp: $74kMr. Mohamed Wa'el Ahmed Hashad (Age 62)CEO & Director Comp: $781.56kMs. Lisa A. Locklear M.B.A. (Age 62)Executive VP & CFO Comp: $248.38kMr. Paul T. Lehr J.D. (Age 56)International Executive Director, General Counsel & Secretary Comp: $554.05kDr. Dan Gincel Ph.D. (Age 53)Senior Vice President of Strategic Collaborations & Scientific Affairs Dr. Nataliya Agafanova M.D. (Age 54)Chief Medical Officer Ms. Elly Ryu (Age 42)VP & Corporate Controller More ExecutivesKey CompetitorsLumos PharmaNASDAQ:LUMOApollomicsNASDAQ:APLMNeuroBo PharmaceuticalsNASDAQ:NRBOIterum TherapeuticsNASDAQ:ITRMSynlogicNASDAQ:SYBXView All CompetitorsInsidersRock SofferBought 31,915 shares on 4/11/2024Total: $75,000.25 ($2.35/share)Mohamed Wa'el Ahmed HashadBought 10,638 shares on 4/11/2024Total: $24,999.30 ($2.35/share)Joshua HareBought 106,383 shares on 4/10/2024Total: $250,000.05 ($2.35/share)Cathy RossBought 500 shares on 1/10/2024Total: $6,550.00 ($13.10/share)Jeffrey PfefferBought 1,000 shares on 12/28/2023Total: $13,500.00 ($13.50/share)View All Insider Transactions LGVN Stock Analysis - Frequently Asked Questions Should I buy or sell Longeveron stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Longeveron in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LGVN shares. View LGVN analyst ratings or view top-rated stocks. What is Longeveron's stock price target for 2024? 1 equities research analysts have issued 12-month price targets for Longeveron's stock. Their LGVN share price targets range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next year. This suggests a possible upside of 284.6% from the stock's current price. View analysts price targets for LGVN or view top-rated stocks among Wall Street analysts. How have LGVN shares performed in 2024? Longeveron's stock was trading at $13.60 at the start of the year. Since then, LGVN shares have decreased by 77.1% and is now trading at $3.12. View the best growth stocks for 2024 here. When is Longeveron's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 9th 2024. View our LGVN earnings forecast. How were Longeveron's earnings last quarter? Longeveron Inc. (NASDAQ:LGVN) released its quarterly earnings data on Tuesday, May, 14th. The company reported ($1.61) earnings per share for the quarter, topping the consensus estimate of ($2.01) by $0.40. The business earned $0.55 million during the quarter, compared to analyst estimates of $0.12 million. Longeveron had a negative net margin of 2,129.24% and a negative trailing twelve-month return on equity of 300.96%. During the same quarter in the previous year, the business posted ($2.20) earnings per share. When did Longeveron's stock split? Longeveron shares reverse split on Wednesday, March 27th 2024. The 1-10 reverse split was announced on Wednesday, March 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, March 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Longeveron IPO? Longeveron (LGVN) raised $30 million in an initial public offering (IPO) on Friday, February 12th 2021. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. served as the underwriters for the IPO. How do I buy shares of Longeveron? Shares of LGVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LGVN) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.